Articles By Jack Cush, MD
The Negotiator
This is going to be my third visit with this patient and I’m not looking forward to it. In the first two, I discovered how sick she was and how, despite my handouts, efforts, insights and words, my educated medical expertise was totally wasted.
Read Article
The RheumNow Week in Review – 10 February 2017
Dr. Jack Cush discusses the news and reports from this week on RheumNow:
Read Article
Chronic Pain Associated with Poverty and Less Education
Poorer and less-educated older Americans are more likely to suffer from chronic pain than those with greater wealth and more education, but the disparity between the two groups is much greater than previously thought, according to new research.
Read Article
Cytoplasmic Autoantibodies in the Anti-Synthetase Syndrome
Patients known to be autoantibody positive (e.g., anti- Jo1) for the anti-synthetase syndrome were assayed by indirect immunofluorescence (IIF) for other reactivities, showing antinuclear staining (ANA) or cytoplasmic staining (Anti-Cyt Ab+).
Read Article
Intra-articular Corticosteroids or Methotrexate for Oligoarticular JIA?
Oligoarticular-onset juvenile idiopathic arthritis accounts for nearly half of all JIA patients. While many of these children will require DMARD therapy, many others are treated with antiinflammatory meds or intra-articular corticosteroids. But the evidence for this latter approach is scant.
Read Article
Novel Peripheral Helper T Cells in RA
US and UK researchers have identified a unique subset of helper T-cells called ‘peripheral helper’ T-cells in the synoviums that may be linked to the pathogenesis of rheumatoid arthritis.
Read Article
NSAIDs Ineffective in Back Pain
The George Institute for Global Health has performed a systematic review of drugs used to treat back pain. Their findings, published in the Annals of the Rheumatic Diseases, shows that only one in six improve their pain with NSAID therapy.
Read Article
Modest Efficacy for Methotrexate in Psoriasis
Doubt remains regarding the appropriateness, efficacy and safety of methotrexate in the treatment of moderate to severe cutaneous psoriasis. Moreover, high dose, subcutaneous MTX has not been studied in a well-designed trial.
Read Article
The RheumNow Week in Review – 3 February 2017
Dr. Jack Cush reviews this week's highlights from RheumNow.
Read Article
Kevzara (Sarilumab) Approved in Canada for RA
Kevzara (sarilumab), an interleukin-6 (IL-6) receptor monoclonal antibody, was approved by Health Canada for use in rheumatoid arthritis (RA).
Read Article
